HighGravityDataEli Lilly — Oct 30, 2025 release
Fiscal 2025 third-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0000059478-25-000251
Showing in the filing
Revenue
“$63.0 billion to $63.5 billion”
Period
FY2025
Measure
GAAP-tied
Source
Prose
All guidance in this release · 12
Revenue for FY2025
“$63.0 billion to $63.5 billion”
EPS (non-GAAP) for FY2025
“$23.00 to $23.70”
Performance margin, reported basis for FY2025
“43.5% and 44.5%”
Performance margin, non-GAAP basis for FY2025
“45.0% and 46.0%”
Other income (expense), non-GAAP basis for FY2025
“$700 million to $600 million”
Estimated effective tax rate (reported) for FY2025
“approximately 19%”
Earnings per share (reported) for FY2025
“$21.80 to $22.50”
EPS (reported) for FY2025
“$21.80 to $22.50”
Earnings per share (non-GAAP) for FY2025
“$23.00 to $23.70”
Other Income/(Expense) (non-GAAP) for FY2025
“Unchanged”
Tax Rate (non-GAAP) for FY2025
“Unchanged”
Tax Rate (reported) for FY2025
“Unchanged”
Exhibit 99.1 · the passage around this item
… earlier in the release
rowth from Mounjaro and Zepbound . • Q3 2025 EPS increased by $5.14 to $6.21 on a reported basis and increased by $5.84 to $7.02 on a non-GAAP basis. • Increased our 2025 full-year revenue guidance to be in the range of $63.0 billion to $63.5 billion; reported EPS guidance raised to be in the range of $21.80 to $22.50 and non-GAAP EPS guidance raised to be in the range of $23.00 to $23.70. • Pipeline progress included positive results in four Phase 3 trials of orforglipron, across type 2 diabetes and obesity, with plans to submit to global regulatory authorities by the end of the year for the treatment of obesity. • Regulatory progress included U.S. FDA approval of Inluriyo (imlunestrant) for certain adults with advanced or metastatic breast cancer. • Manufacturing progress included announcements of two new facilities in Virginia and Texas, and the expansion of Lilly's existing Puerto Rico site. INDIANAPOLIS, October 30, 2025 - Eli Lilly and Company (NYSE: LLY) today announced its financial results for the third-quarter of 2025. “Lilly delivered another strong quarter, with 54% revenue growth year-over-year driven by continued demand for our incretin portfolio,” said David A. Ricks, Lilly chair and CEO. “We advanced orforglipron through four additional Phase 3 trials, enabling global obesity submissions by year-end, and we achieved U.S. FDA approval of Inluriyo (imlunestrant)—marking key progress across our pipeline. We contin
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.